Skip to content

Allogene Therapeutics ALLO Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$42.61M-9.8%-$38.81M+6.3%-$41.4M+18.7%-$50.94M+14.7%-$59.73M+0.3%
$2.87M-6.1%$3.06M-1.3%$3.1M-0.3%$3.11M+0.2%$3.1M-4.1%
$8.27M+1.7%$8.13M-6.0%$8.65M-0.4%$8.69M-28.7%$12.18M-5.4%
-$12.91M+53.2%-$27.6M+7.0%-$29.69M+23.9%-$39.03M+26.3%-$52.93M-44.2%
$9K$0-100%$243K+452%$44K-55.6%$99K-61.5%
-$29.59M-188%$33.61M+182%$11.94M-72.8%$43.84M+610%$6.18M-88.8%
$21.12M+169%$7.86M+143%$3.24M-36.2%$5.07M-63.7%$13.99M+144%
-$21.38M-$14.52M-$32.76M
-$12.92M+53.2%-$27.6M+7.8%-$29.93M+23.4%-$39.07M+26.3%-$53.03M-43.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Allogene Therapeutics generate?
Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
What is Allogene Therapeutics's free cash flow?
After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
Where does Allogene Therapeutics's cash flow data come from?
Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.